Your browser doesn't support javascript.
loading
Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1.
Staniszewska, Anna D; Pilger, Domenic; Gill, Sonja J; Jamal, Kunzah; Bohin, Natacha; Guzzetti, Sofia; Gordon, Jacob; Hamm, Gregory; Mundin, Gill; Illuzzi, Giuditta; Pike, Andy; McWilliams, Lisa; Maglennon, Gareth; Rose, Jonathan; Hawthorne, Glen; Cortes Gonzalez, Miguel; Halldin, Christer; Johnström, Peter; Schou, Magnus; Critchlow, Susan E; Fawell, Stephen; Johannes, Jeffrey W; Leo, Elisabetta; Davies, Barry R; Cosulich, Sabina; Sarkaria, Jann N; O'Connor, Mark J; Hamerlik, Petra.
Affiliation
  • Staniszewska AD; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Pilger D; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Gill SJ; Oncology Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.
  • Jamal K; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Bohin N; Oncology Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.
  • Guzzetti S; DMPK, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Gordon J; Oncology R&D, AstraZeneca, Boston, Massachusetts.
  • Hamm G; Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.
  • Mundin G; DMPK, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Illuzzi G; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Pike A; DMPK, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • McWilliams L; Discovery Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.
  • Maglennon G; Pathology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.
  • Rose J; Animal Sciences and Technologies, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.
  • Hawthorne G; Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.
  • Cortes Gonzalez M; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Halldin C; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Johnström P; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Schou M; PET Science Centre at Karolinska Institutet, Precision Medicine and Biosamples, Oncology R&D, Stockholm, Sweden.
  • Critchlow SE; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Fawell S; PET Science Centre at Karolinska Institutet, Precision Medicine and Biosamples, Oncology R&D, Stockholm, Sweden.
  • Johannes JW; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Leo E; Oncology R&D, AstraZeneca, Boston, Massachusetts.
  • Davies BR; Chemistry, Oncology R&D, AstraZeneca, Boston, Massachusetts.
  • Cosulich S; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Sarkaria JN; Projects Group, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • O'Connor MJ; Projects Group, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Hamerlik P; Mayo Clinic, Rochester, Minnesota.
Clin Cancer Res ; 30(7): 1338-1351, 2024 Apr 01.
Article in En | MEDLINE | ID: mdl-37967136
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Glioma Limits: Animals / Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2024 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Glioma Limits: Animals / Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2024 Document type: Article Affiliation country: